DF and better Unichem operations drive earnings

Company
18 Nov 2024
5 Min read 
  • IPCA Laboratories reported 2QFY25 results with a slight miss on performance.
  •  Revenue was better than expected, driven by domestic formulations and exports.
  •  Margins were lower than estimated due to higher operating expenses.
  •  The company is preparing for re-launch/new offerings in the US generics market.
  •  IPCA is working on multiple fronts to maintain strong earnings momentum.
  •  The company expects a 26% earnings CAGR over FY25-27.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority